var data={"title":"Timolol (ophthalmic): Pediatric drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Timolol (ophthalmic): Pediatric drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390751?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=timolol-ophthalmic-drug-information\" class=\"drug drug_general\">see &quot;Timolol (ophthalmic): Drug information \t&quot;</a> and <a href=\"topic.htm?path=timolol-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Timolol (ophthalmic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600186\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Betimol;</li>\n      <li>Istalol;</li>\n      <li>Timoptic;</li>\n      <li>Timoptic Ocudose;</li>\n      <li>Timoptic-XE</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600187\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Timop;</li>\n      <li>Dom-Timolol;</li>\n      <li>Odan-Timol;</li>\n      <li>PMS-Timolol;</li>\n      <li>Sandoz-Timolol;</li>\n      <li>Timolol Maleate-EX;</li>\n      <li>Timoptic;</li>\n      <li>Timoptic-XE</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10536947\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Beta-Adrenergic Blocker</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Beta-Adrenergic Blocker, Ophthalmic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10536964\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=timolol-ophthalmic-drug-information\" class=\"drug drug_general\">see &quot;Timolol (ophthalmic): Drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Glaucoma:</b>  Infants, Children, and Adolescents: Use lowest effective dose; the gel formulation may be preferable due to decreased systemic absorption (Coppens 2009): Ophthalmic: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gel-forming solution (Timolol GFS, Timoptic-XE): Instill 1 drop (either 0.25% or 0.5%) once daily into affected eye(s) (Coppens 2009; Moore 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution: Limited data available: Initial: 0.25% solution, instill 1 drop twice daily into affected eye(s);  increase to 0.5% solution if response not adequate; decrease to 1 drop once daily into affected eye(s) if controlled; maximum dose: 1 drop (0.5% solution)/dose (Hoskins 1985; Moore 2007) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Infantile hemangioma, superficial:</b> Limited data available: Infants and Children: Topical: Gel-forming solution: Apply 1 drop of the 0.5% gel-forming solution twice daily to the site (Chakkittakandiyil 2012; Chan 2013; Chen 2013; Lee 2013; Pope 2010).  The largest experience is a multicenter retrospective report describing use in over 60 patients which showed improvement in all but one patient with a mean duration of treatment of 3.4 &plusmn; 2.7 months (Chakkittakandiyil  2012). A smaller, randomized trial compared timolol 0.5% gel (n=15) to placebo (n=17) on superficial infantile lesions covering various areas of the body; initial lesion improvements were observed after 12 to 16 weeks, and significant color changes reported at week 24 (Chan 2013). A smaller (n=13) retrospective, open-label trial also showed success with two drops of 0.25% timolol gel-forming solution twice daily on periocular infantile hemangiomas (Chambers 2012). Timolol was reported as being well tolerated in the trials. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Glaucoma:</b> Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution: Initial: 0.25% solution, instill 1 drop twice daily into affected eye(s); increase to 0.5% solution if response not adequate; decrease to 1 drop/day if controlled; do not exceed 1 drop twice daily of 0.5% solution.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Istalol: Instill 1 drop (0.5% solution) once daily into affected eye(s) in the morning</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gel-forming solution (Timolol GFS, Timoptic-XE): Instill 1 drop (either 0.25% or 0.5%) once daily into affected eye(s) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600295\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel Forming Solution, Ophthalmic, as maleate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Timoptic-XE: 0.25% (5 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Timoptic-XE: 0.25% (5 mL) [contains tromethamine]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Timoptic-XE: 0.5% (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25% (5 mL); 0.5% (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic, as hemihydrate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Betimol: 0.25% (5 mL); 0.5% (5 mL, 10 mL, 15 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic, as maleate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Istalol: 0.5% (2.5 mL, 5 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Timoptic: 0.25% (5 mL); 0.5% (5 mL, 10 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25% (5 mL, 10 mL, 15 mL); 0.5% (2.5 mL, 5 mL, 10 mL, 15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic, as maleate [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Timoptic Ocudose: 0.25% (60 ea); 0.5% (60 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600189\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10536965\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Ophthalmic:  Administer other topically applied ophthalmic mediations at least 10 minutes prior timolol</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Wash hands before use; invert closed bottle and shake gel once before use; remove cap carefully so that tip does not touch anything; hold bottle between thumb and index finger; use index finger of other hand to pull down the lower eyelid to form a pocket for the eye drop and tilt head back; place the dispenser tip close to the eye and gently squeeze the bottle to administer 1 drop; remove pressure on bottle after a single drop has been released; <b>do not allow the dispenser tip to touch the eye</b>; replace cap and store bottle in an upright position in a clean area; do <b>not</b> enlarge hole of dispenser; do <b>not</b> wash tip with water, soap, or any other cleaner. Some solutions contain benzalkonium chloride; wait at least 15 minutes after instilling solution before inserting soft contact lenses. With solution, apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration, to decrease systemic absorption of ophthalmic drops (Urtti 1993; Zimmerman 1982)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Wash hands. Apply drop to hemangioma site area and rub in gently to cover entire hemangioma (Chambers 2012; Chan 2013) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600227\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timoptic in OcuDose: Store in the protective foil wrap and use within 1 month after opening foil package.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10536948\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension (Timolol GFS: FDA approved in pediatric patients [age not specified] and adults; other timolol products: FDA approved in adults); has also been used topically for treatment of infantile hemangioma </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600171\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Timolol may be confused with atenolol, Tylenol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Timoptic may be confused with Betoptic S, Talacen, Viroptic</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bottle cap color change: Timoptic: Both the 0.25% and 0.5% strengths are now packaged in bottles with yellow caps; previously, the color of the cap on the product corresponded to different strengths.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Betimol [US] may be confused with Betanol brand name for metipranolol [Monaco]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600212\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, bradycardia, cardiac arrhythmia, cardiac failure, cerebral ischemia, cerebrovascular accident, claudication, cold extremities, edema, heart block, hypertension, hypotension, palpitations, Raynaud's phenomenon</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Amnesia, anxiety, confusion, depression, disorientation, dizziness, drowsiness, exacerbation of myasthenia gravis, hallucination, headache, insomnia, nervousness, nightmares, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, exacerbation of psoriasis, pemphigoid-like lesion, psoriasiform eruption, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypoglycemia (masked), decreased libido</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, diarrhea, dyspepsia, nausea, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence, Peyronie&rsquo;s disease, retroperitoneal fibrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Systemic lupus erythematosus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blepharitis, blepharoptosis, blurred vision, burning sensation of eyes, cataract, choroidal detachment (following filtration surgery), conjunctival injection, conjunctivitis, cystoid macular edema, decreased corneal sensitivity, decreased visual acuity, diplopia, eye discharge, eye pain, eye pruritus, foreign body sensation of eye, hyperemia, keratitis, lacrimation, stinging of eyes, visual disturbance (including refractive changes), xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, cough, dyspnea, nasal congestion, pulmonary edema, respiratory failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600196\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to timolol or any component of the formulation; bronchial asthma or history of bronchial asthma; severe chronic obstructive pulmonary disease (COPD); sinus bradycardia; second- or third-degree atrioventricular block; overt heart failure; cardiogenic shock</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for Ophthalmic Beta-Adrenergic Blocking Agents is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600208\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic reactions: Use with caution in patients with history of atopy or a history of severe anaphylaxis to a variety of allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Choroidal detachment: Beta-blockade and/or other aqueous suppressive therapy have been associated with choroidal detachment following filtration procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular disease: Use with caution in cerebrovascular insufficiency; consider alternative therapy for patients with signs/symptoms of decreased cerebral blood flow after therapy initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus (especially labile diabetes); may potentiate hypoglycemia and/or mask signs and symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Use with caution in patients with compensated heart failure and monitor for a worsening of the condition; may lead to heart failure in patients without a history of heart failure. Use is contraindicated in overt heart failure. In a scientific statement from the American Heart Association, timolol has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen disease or other myasthenic symptoms (eg, diplopia, ptosis, and generalized weakness).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vascular disease (PVD) and Raynaud disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease. Use with caution and monitor for progression of arterial obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring. Severe respiratory reactions, including fatalities due to bronchospasm in patients with asthma, have been reported with ophthalmic use. Use is contraindicated in bronchial asthma or history of bronchial asthma and severe COPD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Some products may contain benzalkonium chloride, which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Absorption: Systemic absorption of timolol and adverse effects may occur with ophthalmic use, including respiratory and cardiovascular effects (eg, bradycardia and/or hypotension). Beta-blocker therapy should not be withdrawn abruptly in order to avoid acute tachycardia, hypertension, and/or ischemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Should not be used alone in angle-closure glaucoma (has no effect on pupillary constriction). Concomitant use of 2 topical beta-blockers is not recommended. Multidose vials have been associated with development of bacterial keratitis; avoid contamination.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: May block systemic effects of beta agonists (eg, epinephrine, norepinephrine); notify anesthesiologist if patient is receiving ophthalmic beta blocker therapy. Patients undergoing planned major surgery should be gradually tapered off therapy (if possible) prior to procedure. If necessary during surgery, effects of beta blocker therapy may be reversed by adrenergic agonists.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27657408\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pediatric patients, particularly infants, may attain higher plasma concentrations compared to adults (Coppens 2004; Passo 1984); systemic adverse effects may occur (eg, hypotension, bradycardia, bronchospasm, and apnea); use the lowest effective dose; some experts advocate avoiding the use of ophthalmic beta-blockers in premature and small infants (Moore 2007). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600214\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600215\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16056&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Apraclonidine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Timolol (Ophthalmic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. <b> Exceptions: </b>Nicergoline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and beta-blockers if possible. If coadministration is necessary, patients should have overnight continuous ECG monitoring conducted after the first dose of fingolimod. Monitor patients for bradycardia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Beta-Blockers may enhance the hypoglycemic effect of Insulins. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Anilidopiperidine): May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.<b> Exceptions: </b>Rifabutin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Citalopram; Escitalopram; FluvoxaMINE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600191\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600192\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Decreased fetal heart rate has been observed following maternal use of ophthalmic timolol during pregnancy (Wagenvoort 1998). Timolol is absorbed systemically following ophthalmic use; additional adverse effects observed with systemic administration may occur. If ophthalmic agents are needed to treat glaucoma in pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease exposure to the fetus (Johnson 2001; Salim 2014; Wagenvoort 1998).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10536966\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor IOP; systemic beta-blocker effects including vital signs (especially in younger patients)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600228\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks both beta<sub>1</sub>- and beta<sub>2</sub>-adrenergic receptors and reduces intraocular pressure by reducing aqueous humor production or possibly increases the outflow of aqueous humor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600230\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Solution:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Intraocular pressure reduction: 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Timolol is measurable in the serum following ophthalmic use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half life elimination: 4 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9600297\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Betimol Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (5 mL): $132.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (10 mL): $280.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Istalol Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (2.5 mL): $195.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Timolol Maleate Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (5 mL): $15.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (10 mL): $32.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (DAILY) (2.5 mL): $161.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Timoptic Ocudose Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (60): $473.51</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (60): $454.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Timoptic Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (5 mL): $197.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (5 mL): $213.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution get-forming</b> (Timolol Maleate Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (5 mL): $198.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (5 mL): $217.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution get-forming</b> (Timoptic-XE Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (5 mL): $230.51</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (5 mL): $252.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10962008\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apimol (AE, ET, JO, QA);</li>\n      <li>Apo-Timop (NZ);</li>\n      <li>Aristomol (BD);</li>\n      <li>Arutimol (LV);</li>\n      <li>Blocanol (FI);</li>\n      <li>Cusimolol (AE, BH, EG, ES, JO, KW, LB, MY, QA, SA);</li>\n      <li>Digaol (FR);</li>\n      <li>Dispatim (DE);</li>\n      <li>Droptimol (MT);</li>\n      <li>Elevex (PH);</li>\n      <li>Geltim (RO);</li>\n      <li>Geltim LP (FR);</li>\n      <li>Glafemak (GR);</li>\n      <li>Glauco (TH);</li>\n      <li>Glauco Oph (HK, TH);</li>\n      <li>Glaucosan (ZA);</li>\n      <li>Glaumol (ET);</li>\n      <li>Glautimol (BR);</li>\n      <li>Glucomol (IN);</li>\n      <li>Glucotim (ET);</li>\n      <li>Glumol (BD);</li>\n      <li>Imot Ofteno al (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Iotim (ZW);</li>\n      <li>Isotic Adretor (ID);</li>\n      <li>Istalol (BM);</li>\n      <li>Ivytimol (ET);</li>\n      <li>Kuzimolol (UA);</li>\n      <li>Lolomit (CO);</li>\n      <li>Lotensin (BD);</li>\n      <li>Noval (GR);</li>\n      <li>Nyogel (AU, BE, FR, GB, IE, IS, ZA);</li>\n      <li>Nyogel LP (FR);</li>\n      <li>Nyolol (AE, BR, CH, CL, EE, FR, HK, IL, PT, PY, RU, SG, SK, TR, TW, UY, VE, VN);</li>\n      <li>Occumol (ZW);</li>\n      <li>Oculan (ZW);</li>\n      <li>Oculol (LK);</li>\n      <li>Oculpres (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ocuper (PH);</li>\n      <li>Ocupres (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Ocupres-E (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Ocutim (ET);</li>\n      <li>Ofal (AR);</li>\n      <li>Oftan (CZ, NO, PH);</li>\n      <li>Oftan Timolol (HK);</li>\n      <li>Oftymol (UA);</li>\n      <li>Ophtamolol (HK);</li>\n      <li>Optamol (PH);</li>\n      <li>Opthil (ID);</li>\n      <li>Optimol (AE, BH, DK, KW, MY, QA, SA, SE);</li>\n      <li>Rysmon TG (KR);</li>\n      <li>Temserin (GR);</li>\n      <li>Tenopt (AU);</li>\n      <li>Tilol (TW);</li>\n      <li>Tiloptic (IL);</li>\n      <li>Timabak (BE, ES, HK, LU);</li>\n      <li>Timacor (FR);</li>\n      <li>Timalen (HR);</li>\n      <li>Timo-COMOD (KR);</li>\n      <li>Timofluid (IE);</li>\n      <li>Timoftol (ES);</li>\n      <li>Timohexal (DE);</li>\n      <li>Timol (TW);</li>\n      <li>Timolast (TW);</li>\n      <li>Timolux (NZ);</li>\n      <li>Timoptic (AT, BB, BG, CH, PE, PL, RO, SK);</li>\n      <li>Timoptic-XE (BB, KR);</li>\n      <li>Timoptol (AE, AU, BE, BF, BH, BJ, CI, CN, CZ, DE, EC, ET, FR, GB, GH, GM, GN, HK, IE, IT, JO, KE, KW, LB, LK, LR, LU, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, PH, PK, PT, SA, SC, SD, SL, SN, TH, TN, TW, TZ, UG, VN, ZA, ZM, ZW);</li>\n      <li>Timoptol-XE (AU, CL, NZ, PE, SG, TW);</li>\n      <li>Timosal (PH);</li>\n      <li>Timosan (EE, FI, LV, SE);</li>\n      <li>Timosol (ET);</li>\n      <li>Tiof (EC);</li>\n      <li>Tiopex (GB);</li>\n      <li>V-Optic (IL);</li>\n      <li>Xilol (BD);</li>\n      <li>Ximex Opticrom (ID);</li>\n      <li>Yesan (GR, MT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Betimol ophthalmic solution (timolol ophthalmic) [prescribing information]. Jacksonville: FL: Vistakon Pharmaceuticlas, LLC; November 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. <i>Pediatr Dermatol</i>. 2012;29(1):28-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/22150436 /pubmed\" target=\"_blank\" id=\"22150436 \">22150436 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chambers CB, Katowitz WR, Katowitz JA, Binenbaum G. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. <i>Ophthal Plast Reconstr Surg</i>. 2012;28(2):103-106. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/22410658 /pubmed\" target=\"_blank\" id=\"22410658 \">22410658 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. <i>Pediatrics</i>. 2013;131(6):e1739-1747.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/23650294 /pubmed\" target=\"_blank\" id=\"23650294 \">23650294 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. <i>Pediatrics</i>. 2013;131(1):99-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/23266916 /pubmed\" target=\"_blank\" id=\"23266916 \">23266916 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coppens G, Stalmans I, Zeyen T, et al, &quot;The Safety and Efficacy of Glaucoma Medication in the Pediatric Population,&quot; <i>J Pediatr Ophthalmol Strabismus</i>, 2009, 46(1):12-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/19213271/pubmed\" target=\"_blank\" id=\"19213271\">19213271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoskins HD, Hetherington J Jr, Magee SD, et al, &ldquo;Clinical Experience With Timolol in Childhood Glaucoma,&rdquo; <i>Arch Ophthalmol</i>, 1985, 103(8):1163-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/4026647/pubmed\" target=\"_blank\" id=\"4026647\">4026647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Istalol ophthalmic solution (timolol ophthalmic) [prescribing information]. Irvine, CA: ISTA Pharmaceuticals Inc; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson SM, Martinez M, and Freedman S, &quot;Management of Glaucoma in Pregnancy and Lactation,&quot; <i>Surv Ophthalmol</i>, 2001, 45(5):449-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/11274697/pubmed\" target=\"_blank\" id=\"11274697\">11274697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee KC, Bercovitch L. Update on infantile hemangiomas.<i> Semin Perinatol</i>. 2013;37(1):49-58. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/23419763 /pubmed\" target=\"_blank\" id=\"23419763 \">23419763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Madadi P, Koren G, Freeman DJ, et al, &quot;Timolol Concentrations in Breast Milk of a Woman Treated for Glaucoma: Calculation of Neonatal Exposure,&quot; <i>J Glaucoma</i>, 2008, 17(4):329-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/18552619/pubmed\" target=\"_blank\" id=\"18552619\">18552619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moore W, Nischal KK. Pharmacologic management of glaucoma in childhood. <i>Paediatr Drugs</i>. 2007;9(2):71-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/17407363 /pubmed\" target=\"_blank\" id=\"17407363 \">17407363 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. <i>Ophthalmology</i>. 1984;91(11):1361-1363. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/6514303 /pubmed\" target=\"_blank\" id=\"6514303 \">6514303 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. <i>Arch Dermatol</i>. 2010;146(5):564-565. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/20479314 /pubmed\" target=\"_blank\" id=\"20479314 \">20479314 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salim S. Glaucoma in pregnancy. <i>Curr Opin Ophthalmol</i>. 2014;25(2):93-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/24469077/pubmed\" target=\"_blank\" id=\"24469077\">24469077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Timolol GFS ophthalmic solution (timolol ophthalmic) [prescribing information]. Fort Worth, TX: Alcon Laboratories, Inc; December 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Timoptic ophthalmic solution (timolol ophthalmic) [prescribing information]. Bridgewater, NJ: Valeant Ophthalmics; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Timoptic XE ophthalmic solution (timolol ophthalmic) [prescribing information].  Bridgewater, NJ: Valeant Ophthalmics; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/8100087 /pubmed\" target=\"_blank\" id=\"8100087 \">8100087 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagenvoort AM, van Vugt JM, Sobotka M, et al, &ldquo;Topical Timolol Therapy in Pregnancy: Is It Safe for the Fetus?&rdquo; <i>Teratology</i>, 1998, 58(6):258-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/9894675/pubmed\" target=\"_blank\" id=\"9894675\">9894675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. <i>Arch Ophthalmol</i>. 1984;102(4):551-553. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/timolol-ophthalmic-pediatric-drug-information/abstract-text/6704011 /pubmed\" target=\"_blank\" id=\"6704011 \">6704011 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16056 Version 163.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9600186\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9600187\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10536947\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10536964\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9600295\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9600189\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10536965\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9600227\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10536948\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9600171\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9600212\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9600196\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9600208\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F27657408\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9600214\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9600215\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9600191\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9600192\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10536966\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9600228\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9600230\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9600297\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10962008\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16056|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=timolol-ophthalmic-drug-information\" class=\"drug drug_general\">Timolol (ophthalmic): Drug information \t</a></li><li><a href=\"topic.htm?path=timolol-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">Timolol (ophthalmic): Patient drug information \t</a></li></ul></div></div>","javascript":null}